← Leaderboards
Anthony D Baughn
Pennsylvania State University, The
$5,912,485
Attributed
$7,559,393
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,559,393 · 4
By mechanism
R01$6,945,517 · 2
R21$613,876 · 2
Top collaborators
- Kenneth C Keiler4 shared
- Courtney C Aldrich2 shared
- Elise Lamont1 shared
Most similar at Pennsylvania State University, The
Same institution · by research overlap
- Kenneth C Keiler$7,478,787
- Andrew James Kerr Conlan$251,056
- Vivek Kapur$697,087
- Marcel A. Behr$251,056
- Kannan Palaniyandi$251,056
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisMycobacterium TuberculosisPredispositionInfectionTuberculosis DrugsTuberculosis TreatmentDrug UsageLoss Of Function MutationPyrazinamideBacillusMediatingAmidasePyrazinamide ResistanceDrug DiscoveryPyrazinoic AcidProdrugsMacrophageAnimal ModelFuturePharmaceutical PreparationsResistanceIn VivoDrug ResistanceIn Vitro
Grant awards (18)
Targeting trans-translation to kill M. tuberculosis non-replicating persister cells$675,928
R01 · FY2025 · AI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis$440,823
R01 · FY2025 · AI · contact PI
Effects of microbial exposure on TB pathogenesis$192,500
R21 · FY2025 · AI
Targeting trans-translation to kill M. tuberculosis non-replicating persister cells$652,094
R01 · FY2024 · AI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis$447,049
R01 · FY2024 · AI · contact PI
Targeting trans-translation to kill M. tuberculosis non-replicating persister cells$660,266
R01 · FY2023 · AI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis$453,149
R01 · FY2023 · AI · contact PI
Targeting trans-translation to kill M. tuberculosis non-replicating persister cells$691,652
R01 · FY2022 · AI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis$459,133
R01 · FY2022 · AI · contact PI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis$464,000
R01 · FY2021 · AI · contact PI
Overcoming Pyrazinamide Resistance with Pyrazinoate-Cephalosporin Conjugates$191,744
R21 · FY2021 · AI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis.$385,000
R01 · FY2020 · AI · contact PI
Overcoming Pyrazinamide Resistance with Pyrazinoate-Cephalosporin Conjugates$229,632
R21 · FY2020 · AI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis.$385,000
R01 · FY2019 · AI · contact PI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis.$383,959
R01 · FY2018 · AI · contact PI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis.$86,006
R01 · FY2018 · AI · contact PI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis.$381,458
R01 · FY2017 · AI · contact PI
The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis.$380,000
R01 · FY2016 · AI · contact PI